Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed attachment file name title grouped question UIN question first answered answering member label
tabling member	label

Search

418383

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dental Services: Children
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 27 July (HL1635), whether they have plans to introduce day surgery appointments for the clearance or extraction of deciduous teeth under general anaesthetic.
tabling member printed	Baroness Gardner of Parkes
uin	HL2177
answer	answer is ministerial correction date of answer 17/09/2015 answer text <p>Many extractions are already carried out on a day case basis; whether the extraction is carried out as a day case or requires an overnight admission is a matter for the clinicians involved.</p><p> </p><p> </p><p> </p><p>NHS England has advised that NHS Lancashire and Greater Manchester have for a number of years commissioned day case surgery as well as overnight admission for children who require a full clearance of deciduous teeth under general anaesthetic.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 17/09/2015 16:27:15 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	3596 label Biography information for Baroness Gardner of Parkes

418384

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Fluoride: Drinking Water
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they have plans to make representations to Manchester City Council to give further consideration to fluoridation of the water supply in Greater Manchester; and whether any such representations will take account of the lower level of tooth decay amongst children in Birmingham, where the water supply has been fluoridated since 1964.
tabling member printed	Baroness Gardner of Parkes
uin	HL2178
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>It has been the policy of successive governments that decisions on water fluoridation are best taken locally. The Health and Social Care Act 2012 gave powers to upper tier and unitary local authorities to make proposals in relation to fluoridation.</p><p> </p><p> </p><p> </p><p>In 2014 Public Health England published a water fluoridation health monitoring report which showed lower levels of tooth decay in areas with water fluoridation.</p><p> </p><p> </p><p> </p><p>Public Health England has also, in 2014, published an evidence informed toolkit for local authorities to support them in planning, reviewing and commissioning oral health improvement interventions for children and young people, including the potential role of water fluoridation.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 21/09/2015 15:12:30 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	3596 label Biography information for Baroness Gardner of Parkes

418385

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Breast Cancer: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of the number of lives that might be saved per annum from licensing bisphosphonates for the treatment of early post-menopausal breast cancer.
tabling member printed	Lord MacKenzie of Culkein
uin	HL2179
answer	answer is ministerial correction date of answer 22/09/2015 answer text <p>Neither the Department nor NHS England have made an assessment of the number of lives that might be saved per annum from licensing bisphosphonates for the treatment of early post-menopausal breast cancer.</p><p> </p><p> </p><p> </p><p>Doctors can already prescribe a drug outside its licensed indications where they judge it to be the most clinically appropriate treatment for an individual patient.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL2180 question first answered 22/09/2015 10:19:17 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2507 label Biography information for Lord MacKenzie of Culkein

418386

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Breast Cancer: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether doctors are free to prescribe bisphosphonates in the treatment of early stage breast cancer despite the fact that it is not presently licensed for that purpose.
tabling member printed	Lord MacKenzie of Culkein
uin	HL2180
answer	answer is ministerial correction date of answer 22/09/2015 answer text <p>Neither the Department nor NHS England have made an assessment of the number of lives that might be saved per annum from licensing bisphosphonates for the treatment of early post-menopausal breast cancer.</p><p> </p><p> </p><p> </p><p>Doctors can already prescribe a drug outside its licensed indications where they judge it to be the most clinically appropriate treatment for an individual patient.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL2179 question first answered 22/09/2015 10:19:18 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2507 label Biography information for Lord MacKenzie of Culkein

418387

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Breast Cancer: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what is the cost to the National Health Service of bisphosphonates and whether they will take steps to encourage the National Institute for Health and Care Excellence to consider the evidence base for the prescription of these drugs in treatment of early stage breast cancer.
tabling member printed	Lord MacKenzie of Culkein
uin	HL2181
answer	answer is ministerial correction date of answer 22/09/2015 answer text <p>The net ingredient cost of prescription items dispensed in the community in England for bisphosphonates<sup>1</sup> in 2014, was £16.813 million<sup>2</sup>.</p><p> </p><p> </p><p> </p><p>In secondary care, the cost in 2014 was £35.841 million<sup>3</sup>.</p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published clinical guidelines on early and locally advanced breast cancer and advanced breast cancer, published in February 2009, and familial breast cancer published in June 2013. NICE periodically reviews its guidance to take account of new and emerging evidence.</p><p> </p><p> </p><p> </p><p>A copy of these clinical guidelines are attached.</p><p> </p><p><em> </em></p><p> </p><p><sup>1 </sup>Bisphosphonates are defined as those included in paragraph 6.6.2 (Bisphosphonates and other drugs affecting bone metabolism) of the British National Formulary (BNF) but excluding denosumab and strontium ranelate.</p><p> </p><p><sup>2 </sup>Source: Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre</p><p> </p><p><sup>3 </sup>Source: Hospital Pharmacy Audit Index (HPAI) provided by IMS Health</p><p> </p><p> </p><p> </p> answering member printed Lord Prior of Brampton attachment 1 file name HL2181 Cost ofbisphosphonates to the NHS.doc attachment 1.pdf title Early and locally advanced breast cancer guideline 2 file name HL2181 Cost ofbisphosphonates to the NHS.doc attachment 2.pdf title Advanced breast cancer guidelines 3 file name HL2181 Cost ofbisphosphonates to the NHS.doc attachment 3.pdf title Familial breast cancer guidelines question first answered 22/09/2015 10:20:06 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2507 label Biography information for Lord MacKenzie of Culkein

418447

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Statins
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to ensure patients prescribed statins can make a choice on what type of statins they receive.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10020
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Decisions regarding the appropriateness of a particular treatment, including statins, should be made by clinicians in partnership with patients. The individual circumstances of each patient should be taken into account, alongside their medical history, needs and preferences.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 21/09/2015 10:04:02 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon

418448

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Smoking
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what information his Department holds on how many people of what age ranges gave up smoking in each of the last five years.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10021
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>The Health and Social Care Information Centre collects this information on behalf of the Department and it is made publicly available at the following web addresses:</p><p> </p><p> </p><p> </p><p><a href="http://www.hscic.gov.uk/catalogue/PUB00417/nhs-stop-smok-serv-eng-2010-2011-tab.xls" target="_blank">http://www.hscic.gov.uk/catalogue/PUB00417/nhs-stop-smok-serv-eng-2010-2011-tab.xls</a></p><p> </p><p> </p><p> </p><p><a href="http://www.hscic.gov.uk/catalogue/PUB07011/stat-stop-smok-eng-apr-11-mar-12-tab1.xls" target="_blank">http://www.hscic.gov.uk/catalogue/PUB07011/stat-stop-smok-eng-apr-11-mar-12-tab1.xls</a></p><p> </p><p> </p><p> </p><p><a href="http://www.hscic.gov.uk/catalogue/PUB12228/stat-stop-smok-serv-eng-apr-12-mar-13-tab1.xls" target="_blank">http://www.hscic.gov.uk/catalogue/PUB12228/stat-stop-smok-serv-eng-apr-12-mar-13-tab1.xls</a></p><p> </p><p> </p><p> </p><p><a href="http://www.hscic.gov.uk/catalogue/PUB14610/stat-stop-smok-serv-eng-apr-13-mar-14-tab.xlsx" target="_blank">http://www.hscic.gov.uk/catalogue/PUB14610/stat-stop-smok-serv-eng-apr-13-mar-14-tab.xlsx</a></p><p> </p><p> </p><p> </p><p><a href="http://www.hscic.gov.uk/catalogue/PUB18002/stat-stop-smok-serv-eng-annual-1415.xlsx" target="_blank">http://www.hscic.gov.uk/catalogue/PUB18002/stat-stop-smok-serv-eng-annual-1415.xlsx</a></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 21/09/2015 10:05:51 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon

418449

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Alzheimer's Disease: Dental Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will commission a study to investigate potential links between dental treatment and Alzheimer's disease.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10023
answer	answer is ministerial correction date of answer 17/09/2015 answer text <p>The Department has no plans to commission a study on the specific risk of transmission of Alzheimer’s disease in dentistry. There is no evidence that Alzheimer's disease can be transmitted through any medical procedure. In dentistry, patients are protected from the risk of infection by either mandatory single use instruments, or where instruments are reused, by guidance on strict decontamination procedures as per the Health Technical Memorandum 01-05: Decontamination in primary care dental practices - 2013 edition.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 17/09/2015 16:09:59 answering member 1201 label Biography information for Alistair Burt
tabling member	4131 label Biography information for Jim Shannon

418454

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ehlers-Danlos Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent discussions his Department has had with health bodies on ensuring timely treatment for sufferers of Ehlers-Danlos syndrome.
tabling member constituency	Bury North
tabling member printed	Mr David Nuttall
uin	9988
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Information on patient outcomes of those diagnosed with Ehlers-Danlos Syndrome (EDS) in London and Greater Manchester is not held centrally by the Department. EDS falls within specialised services managed by NHS England.</p><p> </p><p> </p><p> </p><p>The UK Strategy for Rare Diseases sets out the Government’s on-going commitment to ensuring that patients with rare diseases, including EDS, have access to high quality services. The Strategy is discussed regularly with health bodies including NHS England. The national specialised service for atypical or complex cases aims to reduce times to diagnosis and reduce the number of hospital appointments required to achieve a specific diagnosis.</p><p> </p><p> </p><p> </p><p>Information about the average time from diagnosis to referral for specialist treatment is not available centrally. Patients suspected of having EDS may be assessed and diagnosed in a wide range of settings. These include United Kingdom regional clinical genetics clinics and various other secondary and tertiary speciality clinics.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9987 9989 question first answered 21/09/2015 10:00:16 answering member 4020 label Biography information for George Freeman
tabling member	4140 label Biography information for Mr David Nuttall

418457

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ehlers-Danlos Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the average length of time is between the diagnosis of a patient with Ehlers-Danlos syndrome and referral for specialist treatment in (a) London and (b) Greater Manchester.
tabling member constituency	Bury North
tabling member printed	Mr David Nuttall
uin	9989
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Information on patient outcomes of those diagnosed with Ehlers-Danlos Syndrome (EDS) in London and Greater Manchester is not held centrally by the Department. EDS falls within specialised services managed by NHS England.</p><p> </p><p> </p><p> </p><p>The UK Strategy for Rare Diseases sets out the Government’s on-going commitment to ensuring that patients with rare diseases, including EDS, have access to high quality services. The Strategy is discussed regularly with health bodies including NHS England. The national specialised service for atypical or complex cases aims to reduce times to diagnosis and reduce the number of hospital appointments required to achieve a specific diagnosis.</p><p> </p><p> </p><p> </p><p>Information about the average time from diagnosis to referral for specialist treatment is not available centrally. Patients suspected of having EDS may be assessed and diagnosed in a wide range of settings. These include United Kingdom regional clinical genetics clinics and various other secondary and tertiary speciality clinics.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9987 9988 question first answered 21/09/2015 10:00:17 answering member 4020 label Biography information for George Freeman
tabling member	4140 label Biography information for Mr David Nuttall